These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 33708112)

  • 1. Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2.
    Chen CZ; Shinn P; Itkin Z; Eastman RT; Bostwick R; Rasmussen L; Huang R; Shen M; Hu X; Wilson KM; Brooks BM; Guo H; Zhao T; Klump-Thomas C; Simeonov A; Michael SG; Lo DC; Hall MD; Zheng W
    Front Pharmacol; 2020; 11():592737. PubMed ID: 33708112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2.
    Chen CZ; Shinn P; Itkin Z; Eastman RT; Bostwick R; Rasmussen L; Huang R; Shen M; Hu X; Wilson KM; Brooks B; Guo H; Zhao T; Klump-Thomas C; Simeonov A; Michael SG; Lo DC; Hall MD; Zheng W
    bioRxiv; 2020 Aug; ():. PubMed ID: 32839771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2.
    Biering SB; Van Dis E; Wehri E; Yamashiro LH; Nguyenla X; Dugast-Darzacq C; Graham TGW; Stroumza JR; Golovkine GR; Roberts AW; Fines DM; Spradlin JN; Ward CC; Bajaj T; Dovala D; Schulze-Gamen U; Bajaj R; Fox DM; Ott M; Murthy N; Nomura DK; Schaletzky J; Stanley SA
    ACS Infect Dis; 2021 Aug; 7(8):2337-2351. PubMed ID: 34129317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening.
    Zhu W; Xu M; Chen CZ; Guo H; Shen M; Hu X; Shinn P; Klumpp-Thomas C; Michael SG; Zheng W
    ACS Pharmacol Transl Sci; 2020 Oct; 3(5):1008-1016. PubMed ID: 33062953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.
    Rodon J; Muñoz-Basagoiti J; Perez-Zsolt D; Noguera-Julian M; Paredes R; Mateu L; Quiñones C; Perez C; Erkizia I; Blanco I; Valencia A; Guallar V; Carrillo J; Blanco J; Segalés J; Clotet B; Vergara-Alert J; Izquierdo-Useros N
    Front Pharmacol; 2021; 12():646676. PubMed ID: 33841165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay.
    Jang WD; Jeon S; Kim S; Lee SY
    Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34234012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Strategies of Antiviral Drug Discovery for COVID-19.
    Mei M; Tan X
    Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2.
    Anwaar MU; Adnan F; Abro A; Khan RA; Rehman AU; Osama M; Rainville C; Kumar S; Sterner DE; Javed S; Jamal SB; Baig A; Shabbir MR; Ahsan W; Butt TR; Assir MZ
    Comput Biol Med; 2022 Feb; 141():105049. PubMed ID: 34823857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repurposing old drugs as antiviral agents for coronaviruses.
    Yang CW; Peng TT; Hsu HY; Lee YZ; Wu SH; Lin WH; Ke YY; Hsu TA; Yeh TK; Huang WZ; Lin JH; Sytwu HK; Chen CT; Lee SJ
    Biomed J; 2020 Aug; 43(4):368-374. PubMed ID: 32563698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2.
    Xiao X; Wang C; Chang D; Wang Y; Dong X; Jiao T; Zhao Z; Ren L; Dela Cruz CS; Sharma L; Lei X; Wang J
    Front Immunol; 2020; 11():586572. PubMed ID: 33324406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput screening assays for SARS-CoV-2 drug development: Current status and future directions.
    Xu T; Zheng W; Huang R
    Drug Discov Today; 2021 Oct; 26(10):2439-2444. PubMed ID: 34048893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry.
    Xu M; Pradhan M; Gorshkov K; Petersen JD; Shen M; Guo H; Zhu W; Klumpp-Thomas C; Michael S; Itkin M; Itkin Z; Straus MR; Zimmerberg J; Zheng W; Whittaker GR; Chen CZ
    SLAS Discov; 2022 Mar; 27(2):86-94. PubMed ID: 35086793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors.
    Zhao Y; Du X; Duan Y; Pan X; Sun Y; You T; Han L; Jin Z; Shang W; Yu J; Guo H; Liu Q; Wu Y; Peng C; Wang J; Zhu C; Yang X; Yang K; Lei Y; Guddat LW; Xu W; Xiao G; Sun L; Zhang L; Rao Z; Yang H
    Protein Cell; 2021 Nov; 12(11):877-888. PubMed ID: 33864621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2.
    Wang S; Sun Q; Xu Y; Pei J; Lai L
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34081143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Repurposing: A Strategy for Discovering Inhibitors against Emerging Viral Infections.
    Dos Santos Nascimento IJ; de Aquino TM; da Silva-Júnior EF
    Curr Med Chem; 2021; 28(15):2887-2942. PubMed ID: 32787752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
    Kandeel M; Abdelrahman AHM; Oh-Hashi K; Ibrahim A; Venugopala KN; Morsy MA; Ibrahim MAA
    J Biomol Struct Dyn; 2021 Sep; 39(14):5129-5136. PubMed ID: 32597315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral pandemic preparedness: A pluripotent stem cell-based machine-learning platform for simulating SARS-CoV-2 infection to enable drug discovery and repurposing.
    Esmail S; Danter W
    Stem Cells Transl Med; 2021 Feb; 10(2):239-250. PubMed ID: 32961040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2.
    Ku KB; Shin HJ; Kim HS; Kim BT; Kim SJ; Kim C
    J Microbiol Biotechnol; 2020 Dec; 30(12):1843-1853. PubMed ID: 33203821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repurposing of potential antiviral drugs against RNA-dependent RNA polymerase of SARS-CoV-2 by computational approach.
    Gangadharan S; Ambrose JM; Rajajagadeesan A; Kullappan M; Patil S; Gandhamaneni SH; Veeraraghavan VP; Nakkella AK; Agarwal A; Jayaraman S; Surapaneni KM
    J Infect Public Health; 2022 Nov; 15(11):1180-1191. PubMed ID: 36240528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.